Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042982 | 0.85 | TDP1 (0.42) | MAPTTDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL10830642 | 0.85 | TDP1 (0.42) | MAPTTDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL7690118 | 0.79 | TDP1 (0.39) | MAPTTDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL4983762 | 0.77 | ALDH1A1 (0.41) | MAPTALDH1A1 | |
| SCHEMBL14745750 | 0.76 | CYP3A4 (0.45) | MAPTTDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL3871245 | 0.73 | TSHR (0.35) | TDP1TSHR | |
| SCHEMBL2036556 | 0.73 | TDP1 (0.40) | MAPTTDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL7573520 | 0.72 | TDP1 (0.42) | MAPTTDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL6483817 | 0.71 | TDP1 (0.44) | MAPTTDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL5227209 | 0.71 | TDP1 (0.41) | MAPTTDP1ALDH1A1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070789-A1 | PROCESS FOR MAKING AMLODIPINE, DERIVATIVES THEREOF, AND PRECURSORS THEREFOR | SLANINA PAVEL | 2008-03-20 | — | — | US | disclosed |
| US-20060167265-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | PETERS THEODORUS H | 2006-07-27 | — | — | US | disclosed |
| EP-1577298-A1 | Process for determining the purity of amlodipine | Bioorganics B.V. (NL) | 2005-09-21 | — | — | EP | disclosed |
| US-20050137405-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | PETERS THEODORUS H A (NL) | 2005-06-23 | — | — | US | disclosed |
| US-6858738-B2 | Process for making amlodipine, derivatives thereof, and precursors therefor | SYNTHON BV (NL) | 2005-02-22 | — | — | US | disclosed |
| US-20030220501-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | SYNTHON IP INC. | 2003-11-27 | — | — | US | disclosed |
| US-6653481-B2 | Used as calcium channel blockers | SYNTHON BV (NL) | 2003-11-25 | — | — | US | disclosed |
| EP-1345901-A2 | PROCESS FOR MAKING AMLODIPINE, DERIVATIVES THEREOF, AND PRECURSORS THEREFOR | Bioorganics B.V. (NL) | 2003-09-24 | — | — | EP | disclosed |
| US-20020143046-A1 | Process for making amlodipine, derivatives therof, and precursors therefor | SYNTHON IP INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002053535-A2 | PROCESS FOR MAKING AMLODIPINE, DERIVATIVES THEREOF, AND PRECURSORS THEREFOR | BIOORGANICS B.V. (NL) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167265-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | CYP4A11, CYP4F11, CACNA1D | MAPT 957/4885TDP1 3769/4885ALDH1A1 1591/4885 |
| US-20050137405-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | CACNA1D, CACNA1S, CACNA1C | MAPT 3435/4885TDP1 3873/4885ALDH1A1 1269/4885 |
| US-20030220501-A1 | Process for making amlodipine, derivatives thereof, and precursors therefor | CACNA1D, CACNA1S, CACNA1C | MAPT 3498/4885TDP1 3434/4885ALDH1A1 677/4885 |
| US-20020143046-A1 | Process for making amlodipine, derivatives therof, and precursors therefor | CACNA1D, CACNA1F, CACNA1S | MAPT 2410/4885TDP1 2276/4885ALDH1A1 1332/4885 |
| US-20080070789-A1 | PROCESS FOR MAKING AMLODIPINE, DERIVATIVES THEREOF, AND PRECURSORS THEREFOR | CACNA1D, CACNA1F, CYP51A1 | MAPT 2593/4885TDP1 2913/4885ALDH1A1 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.